News | July 24, 2024
Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Subscribe To Our Newsletter & Stay Updated
